Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Helfrich

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|January 26, 2000
CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitroG Molema, J W Tervaert, B J Kroesen, et al.
Neuropathology and Applied Neurobiology|January 28, 2010
Review: on TRAIL for malignant glioma therapy?J M A Kuijlen, E Bremer, J J A Mooij, et al.
International Journal of Cancer|April 16, 1998
Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomasW Helfrich, B J Kroesen, R C Roovers, et al.
Leukemia|November 24, 2006
The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cellsB ten Cate, D F Samplonius, T Bijma, et al.
Toxicology and Applied Pharmacology|March 4, 2015
Developmental exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin alters DNA methyltransferase (dnmt) expression in zebrafish (Danio rerio)Neelakanteswar Aluru, Elaine Kuo, Lily W Helfrich, et al.
Current Pharmaceutical Design|November 11, 2008
Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticalsH J K Ananias, I J de Jong, R A Dierckx, et al.
Leukemia|March 6, 2009
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stabilityB ten Cate, E Bremer, M de Bruyn, et al.
British Journal of Cancer|January 1, 1997
A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral bloodW Helfrich, R ten Poele, G J Meersma, et al.
Chemical Communications (Cambridge, England)|August 22, 2019
A light-responsive liposomal agent for MRI contrast enhancement and monitoring of cargo deliveryF Reeßing, M C A Stuart, D F Samplonius, et al.
International Journal of Cancer|June 9, 1995
Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat modelB J Kroesen, W Helfrich, A Bakker, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|January 26, 2000
CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitroG Molema, J W Tervaert, B J Kroesen, et al.
Neuropathology and Applied Neurobiology|January 28, 2010
Review: on TRAIL for malignant glioma therapy?J M A Kuijlen, E Bremer, J J A Mooij, et al.
International Journal of Cancer|April 16, 1998
Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomasW Helfrich, B J Kroesen, R C Roovers, et al.
Leukemia|November 24, 2006
The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cellsB ten Cate, D F Samplonius, T Bijma, et al.
Toxicology and Applied Pharmacology|March 4, 2015
Developmental exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin alters DNA methyltransferase (dnmt) expression in zebrafish (Danio rerio)Neelakanteswar Aluru, Elaine Kuo, Lily W Helfrich, et al.
Current Pharmaceutical Design|November 11, 2008
Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticalsH J K Ananias, I J de Jong, R A Dierckx, et al.
Leukemia|March 6, 2009
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stabilityB ten Cate, E Bremer, M de Bruyn, et al.
British Journal of Cancer|January 1, 1997
A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral bloodW Helfrich, R ten Poele, G J Meersma, et al.
Chemical Communications (Cambridge, England)|August 22, 2019
A light-responsive liposomal agent for MRI contrast enhancement and monitoring of cargo deliveryF Reeßing, M C A Stuart, D F Samplonius, et al.
International Journal of Cancer|June 9, 1995
Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat modelB J Kroesen, W Helfrich, A Bakker, et al.
Pageof 5